- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01398150
Cranberry Enhances Human Immune Function and Reduces Illness
September 16, 2011 updated by: University of Florida
The purpose of this study is to determine whether consuming a beverage made with cranberry polyphenols and proanthocyanidins is effective in modifying immune function by enhancing immune cell proliferation, cytokine production, and antioxidant capacity.
If immune cell proliferation is improved, the subjects are expected to have fewer cold and flu symptoms.
Study Overview
Status
Completed
Conditions
Detailed Description
The study will be conducted as a randomized, double blind, placebo-controlled parallel trial.
Subjects will be randomly assigned to either the Treatment (cranberry beverage) group or the Placebo group and each will be instructed to consume the test beverages twice a day for 70 days.
The beverage is not commercially prepared juice, but is a beverage prepared with an extract of cranberry that contains polyphenols and proanthocyanidins.
Blood is taken at baseline, and day 70.
Subjects are given a diary to keep a record of their cold and flu symptoms.
Serum is used to determine the antioxidant activity by the ORAC method.
Peripheral blood mononuclear cells are isolated from the blood draw and used fresh, cultured for 24 hours or cultured for 10 days.
Freshly isolated cells will be used to determine αβ-T, γδ-T, B and NK cell numbers and then cultured in autologous serum for 10 days to determine how well they proliferate.
The supernatant of 24 hour cultures will be used for cytokine determination.
If cells have been primed by the beverage made with cranberry compounds, the investigators expect the cells to proliferate to a greater extent and have modified cytokine production compared to placebo.
If the beverage made with cranberry compounds enhances the proliferation of one or more of these cell types (αβ-T, γδ T, B or NK cell), then it is possible that there will be fewer cold and flu symptoms in the group consuming the cranberry beverage.
Incidence of illness is not expected to change, only the severity of the illness.
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32611
- 449 Food Science and Human Nutrition Department
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Health male or non-pregnant female
- Between the ages of 21 and 50
- BMI between 18 and 35
Exclusion Criteria:
- High blood pressure define as 140/90
- Ongoing or chronic illness or infection
- On hypertensive medication, immunosuppressive drugs, antibiotics, or chronic use of NSAIDS
- Taking plant-based dietary supplements, antioxidant supplements, or probiotics
- Vegetarian or strict vegan
- Consume more than 1 cup of tea (iced or hot) per day
- Consumes more than 2 glasses of alcoholic beverages per day
- Consume more than 7 fruits and vegetables per day
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sweetened Beverage
looks like and is given in the same way as the experimental treatment but contains no active ingredient
|
one 15 ounce bottle of beverage consumed daily
|
Experimental: Cranberry Beverage
15 ounce bottle of cranberry beverage consumed daily for 70 days
|
one 15 ounce bottle consumed daily for 70 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physiological modifications to immune cell function
Time Frame: 70 days
|
Proliferation of γδ-T cells when cultured ex vivo in autologous serum
|
70 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cold and flu symptoms
Time Frame: 70 days
|
Incidence and severity of cold and flu symptoms, total and individual.
Other signs of severity, for example, visits to doctor or health clinic, reduction in daily activities, medications prescribed or purchased OTC.
|
70 days
|
Anti-inflammatory outcome
Time Frame: 70 days
|
Serum antioxidant status, cytokine production and proliferation of αβ-T, B and NK cells
|
70 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (Actual)
May 1, 2009
Study Completion (Actual)
May 1, 2009
Study Registration Dates
First Submitted
July 18, 2011
First Submitted That Met QC Criteria
July 19, 2011
First Posted (Estimate)
July 20, 2011
Study Record Updates
Last Update Posted (Estimate)
September 20, 2011
Last Update Submitted That Met QC Criteria
September 16, 2011
Last Verified
February 1, 2010
More Information
Terms related to this study
Other Study ID Numbers
- CB-79545
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Humans
-
Central Institute of Mental Health, MannheimCompleted
-
University of FloridaMushroom CouncilCompleted
-
Regional Hospital HolstebroCompletedHealthy HumansDenmark
-
Philips Clinical & Medical Affairs GlobalActive, not recruitingHealthy Humans | Vital Signs MonitoringUnited States
-
Cedars-Sinai Medical CenterTerminatedDexamethasone Effect on miRNA Profile in Healthy HumansUnited States
-
University of FloridaWakunaga Pharmaceutical Co., Ltd.CompletedImprovement in Immune Cell Function in Healthy HumansUnited States
-
PfizerCompletedHealthy Volunteers | Adult | Drug Interactions | HumansBelgium
-
University of ZurichCompletedAltered Waking States of Consciousness in Healthy HumansSwitzerland
-
Catabasis PharmaceuticalsCompletedAssessment of Mechanistic Blood Biomarkers in Healthy HumansUnited States
-
University of CopenhagenCompletedSynbiotics | Healthy Humans | Composition of Gut Microbiota | Short and Branched-chain Fatty AcidsDenmark
Clinical Trials on Beverage made to look like the cranberry beverage
-
Children's Hospital of PhiladelphiaNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | ObesityUnited States
-
Assembly BiosciencesCompleted